ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that it has received clearance from Health Canada to market and begin distribution of its new Propaq® MD Monitor/Defibrillator and Propaq M Monitor to military customers and air medical operations in Canada. Health Canada approval is similar to U.S. Food and Drug Administration clearance.
Both the Propaq MD and the Propaq M were developed with grants facilitated from the U.S. Army Medical Research and Development Command, and designed specifically to meet the tough demands of battlefield medicine, which encompass air transport and evacuation, and the highly mobile ground, sea and air deployments of medical assets. To this end, the Propaq MD and Propaq M meet an unprecedented number of military and international standards related to durability, environmental operation and storage extremes, radio frequency emissions, and susceptibility to spurious electrical and radio frequency noise. Both are rated at the most stringent IP55 rating for dust and water ingress.
The Propaq MD is an ultra-lightweight compact device with highly sophisticated, advanced capabilities that combine the well-accepted and proven features of the Propaq monitors with the clinically superior therapeutic capabilities of ZOLL defibrillation and non-invasive pacing technologies. The Propaq MD is 60 percent smaller and 40 percent lighter than other similar monitor/defibrillators. It is two pounds lighter than the current military vital signs monitor, the Propaq 206, even with defibrillation and pacing added.
The Propaq MD provides an unmatched combination of capabilities that include a large, high-contrast color LCD display capable of viewing up to four waveforms simultaneously, as well as a full 12-lead ECG for on-screen review. It also offers a unique night vision goggle (NVG) mode for military and air medical nighttime operation. All physiological monitoring parameter values, including heart rate, SpO2, ETCO2, respiration, non-invasive blood pressure, two temperatures, and three invasive pressures, are shown in large color-coded numeric formats. The device is capable of monitoring all patients, whether adult, pediatric or neonatal. Alarms are provided for all parameters.
A new battery system and AC power charger provide worldwide land, sea and air operating capability. The system can monitor all physiological parameters, including three invasive pressures and two temperature channels, for over six hours on a single battery charge.
Propaq M Companion Model
The Propaq M is a companion monitor-only version of Propaq MD. It has been developed to have a completely identical and common interface for operation, batteries, power supplies, blood pressure cuffs, accessories, data and cables, but without therapeutic defibrillation and pacing capability. These two products, when combined, meet the most expansive needs of the military for patient care in difficult environments. In addition to the common interfaces between the two units, virtually all existing Propaq monitor accessories, cable connectors, and ZOLL M Series® CCT defibrillation accessories currently used in military applications will be forward compatible with the new products.
“With their advanced capabilities and compact size, the approval of these products by Health Canada will enable military air and medical organizations in Canada to provide the most advanced critical care to patients,” said Jonathan A. Rennert, President of ZOLL. “Their small footprint results in more cabin space and reduced weight, making it easy to mount inside the aircraft.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company in 2007, 2008, and 2009, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit zoll.com.
Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 17, 2010. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.
Copyright © 2011 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. M Series and ZOLL are registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Propaq is a registered trademark of Welch Allyn. All product names are the property of their respective owners.
A. Ernest Whiton, Chief Financial Officer
ZOLL Medical Corporation
P: +1 (978) 421-9655